Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali's Shareholders of the Previously Announced Business Combination
1. Denali shareholders approved merger with Semnur Pharmaceuticals. 2. The Business Combination is expected to close in September 2025. 3. Scilex focuses on non-opioid pain management products, addressing high unmet needs. 4. SP-102, a key product, has completed Phase 3 studies with Fast Track status. 5. Market opportunities exist in non-opioid therapies for chronic pain management.